Support Centre
31 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Canadian Bronchiolitis Epinephrine Steroid Trial
DOI 10.1186/ISRCTN56745572
ClinicalTrials.gov identifier
EudraCT number
Public title Canadian Bronchiolitis Epinephrine Steroid Trial
Scientific title A randomised controlled trial of nebulised epinephrine and oral dexamethasone in the treatment of outpatients with bronchiolitis
Acronym CanBEST
Serial number at source MCT-67276
Study hypothesis We hypothesise that children presenting to the Emergency Department (ED) with bronchiolitis and who are treated with nebulised epinephrine and/or oral dexamethasone will have fewer hospitalisations and a shorter, less severe illness.
Lay summary
Ethics approval Children's Hospital of Easter Ontario Research Ethics Board gave approval in May 2004.
Study design Randomised controlled trial
Countries of recruitment Canada
Disease/condition/study domain Bronchiolitis
Participants - inclusion criteria 1. Age 6 weeks to 12 months, either sex
2. Respiratory distress assessment instrument (RDAI) score of greater than 3 and less than 15
3. Diagnosis of bronchiolitis
Participants - exclusion criteria 1. Asthma or any previous episode of wheezing treated with bronchodilators
2. Chronic cardiopulmonary disease
3. Presence of varicella or recent close contact
4. Severe respiratory distress
5. Recent treatment with oral or inhaled steroids
6. Insurmountable language barrier
7. Any child born at less than 37 weeks gestation who is less than 6 weeks corrected age
Anticipated start date 01/04/2004
Anticipated end date 31/03/2008
Status of trial Completed
Patient information material
Target number of participants 800
Interventions 1. Oral dexamethasone
2. Nebulised epinephrine

Trial details received: 12 Sept 2005
Primary outcome measure(s) Admission to hospital up to 7 days after enrolment
Secondary outcome measure(s) 1. Time to discharge
2. Length and severity of symptoms
3. Change in RDAI
4. Economic costs
5. Change in oxygen saturation from baseline at times 60, 120, 180 and 240 minutes
6. Co-interventions
7. Return to be evaluated by health care provider for on-going symptoms related to bronchiolitis
8. Adverse events
Sources of funding Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-67276)
Trial website
Publications 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19439742
Contact name Dr  Amy Catherine  Plint
  Address Children's Hospital of Eastern Ontario
401 Smyth Road
  City/town Ottawa
  Zip/Postcode K1H 8L1
  Country Canada
  Tel +1 8 737 7600 ext. 3237
  Fax +1 8 738 4852
  Email plint@cheo.on.ca
Sponsor Children's Hospital of Eastern Ontario (Canada)
  Address 401 Smyth Road
  City/town Ottawa
  Zip/Postcode K1H 8L1
  Country Canada
  Tel +1 8 737 7600
  Fax +1 8 738 4801
  Email webmaster@cheo.on.ca
Date applied 26/09/2005
Last edited 15/05/2009
Date ISRCTN assigned 26/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.